Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease

16 Jan 2008

Abstract excerpt

Intracellular antibodies (intrabodies) and the chaperone, heat shock protein 70 (Hsp70), have each shown potential as therapeutics for neurodegenerative diseases in vitro and in vivo. Investigating combinational therapy in an established Drosophila model of Huntington's disease (HD), we show that Hsp70 and intrabody actually affect different aspects of the disease. Overexpression of human Hsp70 resulted in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibromyalgia and Chronic Fatigue Syndrome Research
Share to Genetic Neurodegenerative Diseases
Share to Heat shock proteins research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18199697
DOI: 10.1096/fj.07-099689

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's diseasePMID 18199697Read ↗

Intrabody applications in neurological disorders: progress and future prospectsSemantic proximity Read ↗

Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.Semantic proximity Read ↗

Human single-chain Fv intrabodies counteract <i>in situ</i> huntingtin aggregation in cellular models of Huntington's diseaseSemantic proximity Read ↗

Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice.Semantic proximity Read ↗

Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disordersSemantic proximity Read ↗

Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.Semantic proximity Read ↗

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodiesSemantic proximity Read ↗

Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Semantic proximity Read ↗

A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila.Semantic proximity Read ↗

Targeting intracellular tau with a gene-encoded single-chain antibody promotes neuronal homeostasis and ameliorates tau pathologySemantic proximity Read ↗

Targeting tauopathy with engineered tau-degrading intrabodies.Semantic proximity Read ↗

Development of a novel VHH intrabody targeting the N17 region of huntingtin exon 1 protein that prevents inclusion body formationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.